Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

Strengthening the Medical Device Clinical Trial Enterprise

CFSAN’s Peer Review for Risk Assessments Robert L. Buchanan, Sherri Dennis, and Marianne Miliotis.

FDA’s “Critical Path” Initiative Presentation to FDA Science Board Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

Standards-Setting in the Context of Regulatory Harmonization Carolyn Compton, M.D., Ph.D., CEO and President Critical Path Institute (C-Path) IOM Workshop.

FDA’s Critical Path to New Medical Product Development Opportunities from the Center for Devices and Radiological Health Larry Kessler, Sc.D., Director.

Introduction to Regulation

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

Office of Cellular Tissue and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Cellular, Tissue, and.

The NIH Roadmap for Medical Research

Drug Discovery Exchange Fellowship Workshop 9 th -10 th December Mike Hardman IMI EMTRAIN Coordinator.

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

Institute on Systems Science and Health- Federal Funding Panel Grace C.Y. Peng, Ph.D. May 25, 2011.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Scientific Data for Evidence- Based Drug Regulation Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration.

APHL Update – FDA Cooperative agreement. The Association of Public Health Laboratories (APHL) has been actively working towards meeting the deliverables.

Leveraging Data Sharing Klaus Romero MD MS FCP Director of Clinical Pharmacology Critical Path Institute.

FDA, PDUFA AND MEDICAL INNOVATION Spring WHAT IS THE FOOD AND DRUG ADMINISTRATION (FDA)? The FDA is an agency within the U.S. Department of Health.

1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.

CPTR Key Accomplishments: Research Resources Group October 3, 2012.

ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Engaging Hospitals in Research: Implementation Science Jose Azar, MD Medical Director,

PhUSE Computational Science Working Groups Solutions Through Collaboration.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

The “Centers for Education & Research on Therapeutics” (CERTs) Funding Opportunity Announcements FOAs RFA-HS and RFA-HS Technical Assistance.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.

Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.

FDA / PhUSE CSS Initiative. Purpose The FDA wishes to establish collaborative working groups to address current challenges related to the access and review.

The CERTs Model for Stakeholder Engagement Public-Private Partnership Hugh H. Tilson, MD, DrPH Chair, CERTs National Steering Committee September 10, 2008.

Annual Meeting of the ASADI – Science Academies as Partners for Improving the Impact of Policies in Africa Session V: Partnership Themes for Development.

Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

1 Vision: To be an agency producing outputs that contribute to optimal efficiency of the Indonesian Universal Health Coverage (UHC) Mission: To ensure.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care The “Centers for Education & Research on Therapeutics” (CERTs)

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD President, The Critical Path Institute.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.

The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.

Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.

1 Office of ASG/CITO Crisis Information Management Strategy UNGIWG-11, Geneva 15 March 2011 A written consent by the UN is required to use the information.

Healthy Homes Initiative: Developing Competencies January 22 – 23, 2004 Baltimore, MD CAPT Patrick O. Bohan, USPHS (Ret)

ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.

21st Century Cures Act: Progress Update

PhUSE Computational Science

Vision, Mission, and Goals

Innovative Medicines Initiative:

PhUSE Computational Science Working Groups

PCORI Research Priorities and Relevant Examples

Data Visualizations Working Group

Chapter 19: The Gerontological Nurse as Manager and Leader

FDA Tox Working Group Which goals of the FDA Roadmap are most important to FDA stakeholders? Integration of predictive technologies Replacing animal tests.

FDA Sentinel Initiative

Trial Funding and Engagement: The NIH Sponsored CTSA Program

Clinical Research Services.  It is very important phase in medical science as it determines the safety and effectiveness of medications and treatment.

Presentation transcript:

Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014 Computational Science Symposium March 16 th – 18 th, 2014 Silver Spring Civic Center, Silver Spring, MD

Our Grand Experiment in Collaboration: “Opportunities Disguised as Problems” in this Fast-Paced, Complex Scientific/Regulatory/Technical Decision-Making World Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014 Computational Science Symposium March 16 th – 18 th, 2014 Silver Spring Civic Center, Silver Spring, MD

Disclaimer This presentation reflects the views of the authors and should not be construed to represent FDA’s views or policies

Computer-Assisted Review of Safety (CARS)

Outline Mission/Vision The Landscape – Motivation PDUFA/FDASIA 21 st Century Review CDER says -- “Show Me the Data” Our “Computational Science”: Is Something Missing? – How Are We Going To “Get There” – CDER/OTS and “Pre-competitive” Collaboration Consortia and Institutional Collaboration Computational Science Symposium (CSS) The Experiment – Some Challenges – Progress Bottom Line

Mission / Vision FDA's mission is to protect and advance public health by helping to speed innovations that provide our nation with safe and effective medical products and that keep our food safe. The Agency achieves this by applying the latest technology and science-based standards to the regulatory challenges presented by drugs, biologics (vaccines, blood products, cell and gene therapy products, and tissues), medical devices, food additives, and, since 2009, tobacco Innovation

PDUFA / FDASIA Efficiency/Predictability of processes Promote innovation Goals Letter: – B. Assessment of the Program … “be evaluated by an independent contractor with expertise in assessing the quality and efficiency of biopharmaceutical development and regulatory review programs.” – XII. IMPROVING THE EFFICIENCY OF HUMAN DRUG REVIEW THROUGH REQUIRED ELECTRONIC SUBMISSIONS AND STANDARDIZATION OF ELECTRONIC DRUG APPLICATION DATA

21 st Century Review

CDER says -- “Show Me the Data”

Copyright CDISC Cooper, 2008

13 CDER says – Show me the data! Assessing Potential Liver Injury [by Analyzing Increases in Serum Alanine Aminotransferase (ALT) and Total Serum Bilirubin (TBILI)] X-axis: Days into Study Individual Patient Profile: Linkage of several data tables using the same timeline Drug experience Data Adverse Event Data Concomitant Drugs Laboratory Data Cooper, 2010

The Critical Path— Data Standards

Our “Computational Science”: Is Something Missing? Tool development / standards – on-going Data quality / documentation / language Submission processes Application: Relevant Science and Decision- Making Training Acceptance by Regulatory Agencies, Industry, Academia

How Are We Going to “Get There”? CDER/OTS and “Pre-competitive” Collaboration SO …

Examples of Public-Private Partnerships with CDER Participation Biomarker Consortium (BC) fNIH International Serious Adverse Events Consortium (iSAEC) Pediatric Anesthesia Safety Initiative (PASI) Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Initiative Cardiac Safety Research Consortium (CSRC) Critical Path Institute (CPath) Coalition Against Major Diseases Consortium (CAMD) Patient Reported Outcomes Consortium (PRO) Predictive Safety Testing Consortium (PSTC) Polycystic Kidney Disease Consortium (PKD) Critical Path to TB Drug Regimens Consortium (CPTR) Clinical Trials Transformation Initiative (CTTI) McCune, 2012

Computational Science Symposium (CSS) 2014 CSS is the 5th in a Series of Annual Computational Science Meetings established to support the work of FDA’s Center for Drug Evaluation and Research (CDER), Office of Computational Science (OSC) 3rd Year working with PhUSE (first two were with the DIA) Intention: To work collaboratively with industry, vendors and regulators in a “non-competitive space” to find solutions and advance the computational sciences/technology associated with the development and regulation of new medical products (drugs, biologics, etc.)

Meetings 2.0 – Computational Science Symposium A different kind of conference: A Collaborative Workgroup Symposium Organizing Committee: Currently defined 4 “working groups” to continue the work throughout the year Supporting collaborative workgroups that will continue until all of the work is done. Technical “Stakeholder Workgroups” – but we are asking you to move beyond “your stake” … act as knowledgeable professionals seeking solutions Work Products, timelines, next steps Job much bigger than these workgroups – this is a start

The Experiment: Tom Sawyer & The Fence

The Experiment Progress Some Challenges

Progress: Current Workgroups Optimizing the Use of Data Standards Development of Standard Scripts for Analysis and Programming Non-Clinical Road-map and Impacts on Implementation Emerging Technologies Emerging Technologies

Progress: Deliverables

Progress: The Wiki

Some Challenges Volunteer / Co-Lead Right Projects Transparency/”Optics” Recognition/Appreciation FDA Involvement – Disclaimer & “Liaison” Wiki and “Agile Communication” Testing and “Socialization of Deliverables”

Adapted from Oliva,, 2007